RTW Investments LLC

Investor type Hedge Fund

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 47
Average round size
info
The average size of a deal this fund participated in
$105M
Portfolio companies 38
Rounds per year 4.27
Lead investments 10
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.19
Exits 16
Key employees Soon

Areas of investment

  • Biotechnology
  • Health Care
  • Pharmaceutical
  • Medical
  • Therapeutics

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of RTW Investments LLC:
Typical Co-investors
RTW Investments LLC is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after RTW Investments LLC:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
9Unicorns Accelerator Fund India, Maharashtra, Mumbai
Cambridge Technology Partners Nyon, Switzerland, Vaud
Chengdu Culture & Tourism Development Group Chengdu, China, Sichuan
Climate Fund Managers -
Exceed Capital Partners California, San Francisco, United States
IC Global Partners Dubai, United Arab Emirates
JM Molina Investments -
Lotus Lake Ventures Beijing, Beijing, China
National Nuclear Security Administration District of Columbia, United States, Washington
National Talents Al Khobar, Ash Sharqiyah, Saudi Arabia
Nomura Asset Management Japan, Tokyo
NovAtel Alberta, Calgary, Canada
One97 Mobility Fund India, Noida, Uttar Pradesh
Prometheus Group North Carolina, Raleigh, United States
Ruyi Capital China, Shanghai
Scentan Ventures Central, Central Region, Singapore
Siena Capital -
Taiyo Kagaku -
Watsco Ventures Florida, Miami, United States

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

ACELYRIN

Biopharma
Biotechnology
Health Care
$250M16 Nov 2021 Los Angeles, California, United States

INBRACE

Consumer
Dental
Health Care
Medical Device
Wellness
$102M08 Sep 2021 Irvine, California, United States

Neurogastrx

Biotechnology
Health Care
Health Diagnostics
Pharmaceutical
$60M26 Aug 2021 California, United States

Artios Pharma

Biopharma
Biotechnology
Medical Device
$150M27 Jul 2021 Cambridge, England, United Kingdom

Umoja Biopharma

Biopharma
Biotechnology
Developer Platform
Information Technology
$210M15 Jun 2021 Seattle, Washington, United States

Alcyone Therapeutics

Biotechnology
Therapeutics
$23M09 Jun 2021 Lowell, Massachusetts, United States

NiKang Therapeutics

Biotechnology
Health Care
Medical
$200M26 May 2021 Wilmington, Delaware, United States

Numab

Biopharma
Biotechnology
Health Diagnostics
Life Science
Medical
Therapeutics
$109M19 May 2021 Zurich, Switzerland

NeoGenomics

Biotechnology
Genetics
Health Care
Health Diagnostics
Medical
Pharmaceutical
$200M05 May 2021 Fort Myers, Florida, United States
News
Neurogastrx Secures $60 Million in Series B Financing and Expands Management Team to Advance Its Pipeline of Transformative Investigational Therapies for Gastrointestinal Disorders

– Neurogastrx, a privately held specialty pharmaceutical company developing transformative therapies for gastrointestinal (GI) disorders, announced the successful completion of a $60m Series B crossover round led by Vivo Capital.
– Other new investors participating in the Series B round include RTW Investments, Samsara BioCapital and Marshall Wace, joining 5AM Ventures, venBio and OrbiMed Advisors.
– Proceeds from the financing will be used to advance the company’s pipeline of GI therapies for serious conditions that impact millions of people yet are not effectively treated.

Umoja Biopharma Raises $210M in Series B Funding

– Umoja Biopharma is a Seattle, WA-based oncology company.
– The company closed a $210m Series B financing.
– The round was co-led by SoftBank Vision Fund 2 and Cormorant Asset Management with participation from new investors, including RTW Investments, LP; Temasek; Presight Capital (the international venture arm of Christian Angermayer’s Apeiron Investment Group); Caas Capital; and an investment fund associated with SVB Leerink.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent RTW Investments LLC?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: